By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...
Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being ...
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
Barchart on MSN
Wave Life Sciences crashes deep into oversold territory as obesity drug data disappoints. Should you buy the dip?
Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity ...
Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...
Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...
Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...
Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long ...
Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...
Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data ...
When Hurricane Helene tore through Western North Carolina in September 2024, it didn't just uproot trees and wash out roads.
With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results